Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0957408/Active-Pharmaceutical-Ingredients-API-Market-in-the-Americas-to-2017---Shift-Towards-Generics-and-Biosimilars-as-South-and-Central-America-Emerges-as-a-Key-Growth-Region.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
Summary
GBI Research's report, "Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region" provides detailed insight into the Americas API market. The research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and CMO growth in the region and its influence on API manufacturing activity towards 2017. Overall, the report presents a comprehensive analysis of the Americas API market, covering all the major parameters.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Americas is the second largest regional market for APIs by revenue in the world. Americas active pharmaceutical ingredients (API) market revenue held a share of around 42.5% of global API market revenue of 108.6 $ billion in 2011. Total revenue generated by the Americas API market was $46.1 billion in 2011 and is expected to grow at a CAGR of 5.6% to reach $63.8 billion by 2017.This will be supported by healthy demand from biotech and generic API sectors.
Scope
- Market revenue data for APIs from 2005 to 2011 and forecast for six years to 2017.
- API markets in key countries in the region: North America ,South and Central America and key countries like the US and Canada
- API industry structure and market trends such as a shift in manufacturing and growth in biotechnology for the Americas region.
- Drivers of the API market, such as the growth of generic drugs, and restraints, such as patent expiries and government initiatives like price reimbursement cut.
- Detailed historical, forecast trend and share analysis of API revenue based on product types (Synthetic and Biotech APIs) in the Americas market and in key countries of the region.
- Detailed historical, forecast trend and share analysis of API revenue based on customer base (Generic and Innovative for Synthetic APIs) (Biosimilars and biologics for Biotech Apis) in the Americas market and in key countries of the region.
- Analysis of API revenue based on therapeutic categories in the North America ,South and Central America
Reasons to buy
- Develop business strategies with the help of specific insights on the Americas API market.
- Identify opportunities and challenges in the Americas API market.
- Invest in the growing segments of the API market.
- Increase future revenue and profitability with the help of insights on the future opportunities and critical success factors in the Americas API market.
- Benchmark your operations and strategies against the major players in the global API market
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
3 Contract Manufacturing Organizations in the Americas' API Manufacturing 12
3.1 Introduction 12
3.1.1 Steps Involved in Outsourcing API Manufacturing to Contract Manufacturing Organizations 12
3.1.2 The US Contract Manufacturing Organization Market 12
4 The Americas' Active Pharmaceutical Ingredients Market 14
4.1 Market Overview 14
4.1.1 API Classification Based on Synthesis Routes 14
4.1.2 Classification Dependent on Customer Base 15
4.2 Industry Structure 15
4.3 Pricing and reimbursement in Americas 16
4.4 The US Healthcare System - Introduction 16
4.4.1 Health Insurance 16
4.5 Brazil Healthcare System - Introduction 17
4.5.1 Public Insurance 17
4.5.2 Private Insurance 17
4.6 The Americas' API Market Drivers 17
4.6.1 Upcoming Patent Expiries are Expected to Alter the API Market Dynamics in the Americas 17
4.6.2 Increasing Uptake of Biologics across Different Therapeutic Areas and Government Initiatives for Biomedical Research to Boost the API Revenues 17
4.6.3 Mergers and Acquisitions have Increased Significantly in the American Pharmaceutical Industry 18
4.6.4 Growth in the Pharmaceutical Industry and Increasing Elderly Population are Driving the Growth of the Americas' API Market 18
4.7 The Americas' API Market Restraints 18
4.7.1 Economic Downturn has Restricted Investment in the Pharmaceutical Industry 18
4.7.2 Lack of Cheap Labor, High Costs and Saturation of the Market are Likely to Hinder New Drug Development in the Region 18
4.7.3 Regulatory Changes Lead to Delays in the Launch of New Drugs 18
4.7.4 Patent Expiries and Increased Consumption of Generics Threatens API Revenue Growth 18
4.7.5 Huge Deficits Provoke Cuts in Healthcare Reimbursement 19
4.8 API Total Revenue Analysis in the Americas 20
4.8.1 The Americas' Revenue Share by Product Types 22
4.8.2 The Americas' Synthetic API Total Synthetic Revenue Analysis (2005–2017) 23
4.8.3 The Americas' Synthetic API Market Revenue Share Analysis by Customer Base in 2011 28
4.8.4 The Americas' Synthetic API Revenue Trend Analysis 2005–2017 29
4.9 The Americas' Biotech API Market Analysis 31
4.9.1 The Americas' Biotech API Revenue Analysis 2005–2017 31
4.10 The Americas' Biotech API Market Revenue Analysis by Customer Base 35
4.10.1 The Americas' Biotech API Market Revenue Share Analysis by Customer Base 35
4.10.2 Patent Expiry of Leading Biologics in the Americas 36
4.10.3 The Americas' Biotech API Revenue Trend Analysis 2005–2017 37
5 North American Active Pharmaceutical Ingredients Market 39
5.1 North American API Market Overview 39
5.2 North American API Market Drivers 39
5.2.1 Continuous Growth in the Pharmaceutical Industry Sustains the API Market's Growth in North America 39
5.2.2 Generic Sector Spurs the Growth of the North American API Market 39
5.2.3 Increasing Focus on Biological Drugs Helps the API Market's Revenue Growth 39
5.3 North American API Market Restraints 39
5.3.1 Recent Economic Slowdown has Restricted the Growth of the Pharmaceutical Industry 39
5.3.2 High Cost of New Drug Development Hampers Innovation 39
5.3.3 Patent Expiries of Blockbuster Molecules will Contain the Growth of the API Market in North America 40
5.4 North American Total API Revenue Analysis based on Synthesis Routes 2005–2017 41
5.5 North American API Revenue Share Analysis by Product Types 2005–2017 43
5.6 North American API Revenue Analysis Dependent on Customer Base 44
5.6.1 North American Synthetic API Revenue Analysis by Customer Base, 2005–2017 44
5.6.2 North American Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017 46
5.6.3 North American Biotech API Revenue Analysis by Customer Base, 2005–2017 47
5.6.4 North American Biotech API Revenue Share Analysis by Customer Base, 2005–2017 49
5.7 North American API Revenue Share Analysis by Therapeutic Applications 50
6 The US Active Pharmaceutical Ingredients Market 52
6.1 The US API Market Overview 52
6.2 The US Total API Revenue Analysis Based on Synthesis Routes 2005–2017 52
6.3 The US API Revenue Share Analysis by Product Types 2005–2017 55
6.4 The US API Revenue Analysis Dependent on Customer Base 56
6.4.1 The US Synthetic API Revenue Analysis by Customer Base, 2005–2017 56
6.4.2 The US Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017 58
6.4.3 The US Biotech API Revenue Analysis by Customer Base, 2005–2017 59
6.4.4 The US Biotech API Revenue Share Analysis by Customer Base, 2005–2017 61
7 Canadian Active Pharmaceutical Ingredients Market 62
7.1 Canadian API Market Overview 62
7.2 Canadian Total API Revenue Analysis based on Synthesis Routes 2005–2017 62
7.3 Canadian API Revenue Share Analysis by Product Types 2005–2017 64
7.4 Canadian API Revenue Analysis Dependent on Customer Base 65
7.4.1 Canadian Synthetic API Revenue Analysis by Customer Base, 2005–2017 65
7.4.2 Canadian Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017 67
7.4.3 Canadian Biotech API Revenue Analysis by Customer Base, 2005–2017 68
7.4.4 Canadian Biotech API Revenue Share Analysis by Customer Base, 2005–2017 70
8 South and Central America Active Pharmaceutical Ingredients Market 71
8.1 South and Central American API Market Overview 71
8.2 South and Central America API Market Drivers 71
8.2.1 Government Initiatives and Growing Investments in the Pharmaceutical Industry Gives a Boost to API Market Growth 71
8.2.2 Improvement in Regulatory Environment 71
8.2.3 Increasing Number of Clinical Trials Leading to Market Growth 71
8.2.4 Ageing Population and Increasing Prevalence of Lifestyle Diseases Fuel Market Growth 71
8.3 South and Central American API Market Restraints 72
8.3.1 Import Dependence for APIs Restricts Market Growth 72
8.3.2 Delay in Regulatory Processes Hinders the Industry Growth 72
8.4 South and Central American Total API Revenue Analysis based on Synthesis Routes 2005–2017 72
8.5 South and Central American API Revenue Share Analysis by Product Types 2005–2017 74
8.6 South and Central American API Revenue Analysis Dependent on Customer Base 75
8.6.1 South and Central American Synthetic API Revenue Analysis by Customer Base, 2005–2017 75
8.6.2 South and Central American Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017 77
8.6.3 South and Central American Biotech API Revenue Analysis by Customer Base, 2005–2017 78
8.6.4 South and Central American Biotech API Revenue Share Analysis by Customer Base, 2005–2017 80
8.7 South and Central American API Revenue Share Analysis by Therapeutic Applications 81
9 Appendix 83
9.1 Abbreviations 83
9.2 Market Definitions 83
9.3 References 83
9.4 Methodology 84
9.4.1 Coverage 84
9.4.2 Secondary Research 84
9.4.3 Primary Research 85
9.4.4 Expert Panel Validation 85
9.5 Contact Us 85
9.6 Disclaimer 85
1.1 List of Tables
Table 1: CMO Market, the US, Revenue Analysis ($bn), 2005–2017 13
Table 2: API, the Americas, Total Revenue Analysis, $m, 2005–2017 21
Table 3: API, the Americas, Revenue Share by Product Types, (%) 2011 22
Table 4: Synthetic API, the Americas, Revenue Analysis, $bn, 2005–2017 25
Table 5: Synthetic API, the Americas, Revenue Share Analysis , (%) 2011 26
Table 6: Synthetic API, the Americas, Revenue Share Analysis by Region, %, 2005–2017 27
Table 7: Synthetic API, the Americas, Revenue Share by Customer Base, (%), 2011 28
Table 8: Synthetic API, the Americas, Revenue Analysis by Customer Base, $m, 2005–2017 30
Table 9: Biotech API, the Americas, Revenue Analysis, ($m), 2005–2017 32
Table 10: Biotech API, the Americas, Revenue Share Analysis, %, 2011 33
Table 11: Biotech API, the Americas, Revenue Share, %, 2005–2017 34
Table 12: The Americas' Biotech API Market, Revenue Share Analysis by Customer Base, 2011 35
Table 13: Biotech API, the Americas, Patent Expiry of Leading Biologics, 2003–2017 36
Table 14: Biotech API, the Americas, Revenue Analysis by Customer Base, $m, 2005–2017 38
Table 15: API Market, North America, Major Drugs to Lose Patent Protection, 2012 and 2016 40
Table 16: API, North America, Revenue Analysis by Product Types, $m, 2005–2017 42
Table 17: API, North America, Revenue Share by Product Type, %, 2005–2017 43
Table 18: Synthetic API, North America, Revenue Analysis by Customer Base, $m, 2005–2017 45
Table 19: Synthetic API, North America, Revenue Share by Customer Base, %, 2005–2017 46
Table 20: Biotech API, North America, Revenue Analysis by Customer Base, $m, 2005–2017 48
Table 21: Biotech API, North America, Revenue Share by Customer Base, %, 2005–2017 49
Table 22: API, North America, Revenue Split by Therapeutic Applications, %, 2011–2017 51
Table 23: API, the US, Revenue Analysis by Product Types, $m, 2005–2017 54
Table 24: API, the US, Revenue Share by Product Type, %, 2005–2017 55
Table 25: Synthetic API, the US, Revenue Analysis by Customer Base, $m, 2005–2017 57
Table 26: Synthetic API, the US, Revenue Share by Customer Base, %, 2005–2017 58
Table 27: Biotech API, the US, Revenue Analysis by Customer Base, $m, 2005–2017 60
Table 28: Biotech API, the US, Revenue Share by Customer Base, %, 2005–2017 61
Table 29: API, Canada, Revenue Analysis by Product Types, $m, 2005–2017 63
Table 30: API, Canada, Revenue Share by Product Type, %, 2005–2017 64
Table 31: Synthetic API, Canada, Revenue Analysis by Customer Base, $m, 2005–2017 66
Table 32: Synthetic API, Canada, Revenue Share by Customer Base, %, 2005–2017 67
Table 33: Biotech API, Canada, Revenue Analysis by Customer Base, $m, 2005–2017 69
Table 34: Biotech API, Canada, Revenue Share by Customer Base, %, 2005–2017 70
Table 35: API, South and Central America, Revenue Analysis by Product Types, $m, 2005–2017 73
Table 36: API, South and Central America, Revenue Share by Product Type, %, 2005–2017 74
Table 37: Synthetic API, South and Central America, Revenue Analysis by Customer Base, $m, 2005–2017 76
Table 38: Synthetic API, South and Central America, Revenue Share by Customer Base, %, 2005–2017 77
Table 39: Biotech API, South and Central America, Revenue Analysis by Customer Base, $m, 2005–2017 79
Table 40: Biotech API, South and Central America, Revenue Share by Customer Base, %, 2005–2017 80
Table 41: API, South and Central America, Revenue Split by Therapeutic Applications, %, 2011–2017 82
1.2 List of Figures
Figure 1: CMO Market, the US, Revenue Analysis ($bn), 2005–2017 13
Figure 2: The Americas' API Market, Product Types 14
Figure 3: API, the Americas, Value Chain, 2011 15
Figure 4: API, the Americas, Total Revenue Analysis, $m, 2005–2017 20
Figure 5: API, the Americas, Revenue Share by Product Types, (%), 2011 22
Figure 6: Synthetic API, the Americas, Revenue Analysis, ($m), 2005–2017 24
Figure 7: Synthetic API, the Americas, Revenue Share Analysis , (%), 2011 26
Figure 8: Synthetic API, the Americas, Revenue Share Analysis by Region, (%), 2005–2017 27
Figure 9: Synthetic API, the Americas, Revenue Share by Customer Base, (%), 2011 28
Figure 10: Synthetic API, the Americas, Revenue Analysis by Product Types, ($m), 2011 29
Figure 11: Biotech API, the Americas, Revenue Analysis,($m), 2005–2017 31
Figure 12: Biotech API, the Americas, Revenue Share Analysis, (%), 2011 33
Figure 13: Biotech API, the Americas, Revenue Share, (%), 2005–2017 34
Figure 14: Biotech API, the Americas, Revenue Share Analysis by Customer Base, (%), 2011 35
Figure 15: Biotech API, the Americas, Revenue Analysis by Customer Base, ($m) Types, 2005–2017 37
Figure 16: API, North America, Revenue Analysis by Product Types, ($m), 2005–2017 41
Figure 17: API, North America, Revenue Share by Product Type, (%), 2005–2017 43
Figure 18: Synthetic API, North America, Revenue Analysis by Customer Base, ($m), 2005–2017 44
Figure 19: Synthetic API, North America, Revenue Share by Customer Base, (%), 2005–2017 46
Figure 20: Biotech API, North America, Revenue Analysis by Customer Base, ($m), 2005–2017 47
Figure 21: Biotech API, North America, Revenue Share by Customer Base, (%), 2005–2017 49
Figure 22: API, North America, Revenue Split by Therapeutic Applications, (%), 2011–2017 50
Figure 23: API, the US, Revenue Analysis by Product Types, ($m), 2005–2017 53
Figure 24: API, the US, Revenue Share by Product Type, (%), 2005–2017 55
Figure 25: Synthetic API, the US, Revenue Analysis by Customer Base, ($m), 2005–2017 56
Figure 26: Synthetic API, the US, Revenue Share by Customer Base, (%), 2005–2017 58
Figure 27: Biotech API, The US, Revenue Analysis by Customer Base, ($m), 2005–2017 59
Figure 28: Biotech API, The US, Revenue Share by Customer Base, (%), 2005–2017 61
Figure 29: API, Canada, Revenue Analysis by Product Types, ($m), 2005–2017 62
Figure 30: API, Canada, Revenue Share by Product Type, (%), 2005–2017 64
Figure 31: Synthetic API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017 65
Figure 32: Synthetic API, Canada, Revenue Share by Customer Base, (%), 2005–2017 67
Figure 33: Biotech API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017 68
Figure 34: Biotech API, Canada, Revenue Share by Customer Base, (%), 2005–2017 70
Figure 35: API, South and Central America, Revenue Analysis by Product Types, ($m), 2005–2017 72
Figure 36: API, South and Central America, Revenue Share by Product Type, (%), 2005–2017 74
Figure 37: Synthetic API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017 75
Figure 38: Synthetic API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017 77
Figure 39: Biotech API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017 78
Figure 40: Biotech API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017 80
Figure 41: API, South and Central America, Revenue Split by Therapeutic Applications, (%), 2011–2017 81
To order this report:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article